2,3,4-Trichloro-N-(5,5-dimethyl-7-oxo-4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)benzenesulfonamide | 375824-98-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,3,4-Trichloro-N-(5,5-dimethyl-7-oxo-4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)benzenesulfonamide
• 英文别名: 2,3,4-trichloro-N-(5,5-dimethyl-7-oxo-4,6-dihydro-1,3-benzothiazol-2-yl)benzenesulfonamide
• CAS: 375824-98-9
• 化学式: C₁₅H₁₃Cl₃N₂O₃S₂
• 分子量: 439.8
• InChiKey: ZMKCHVYBBCOVSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  113
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-氨基-5,5-二甲基-5,6-二氢-4H-苯并噻唑-7-酮 、 2,3,4-三氯苯磺酰氯 以to give a white solid (47.2 mg) with purity >90%的产率得到2,3,4-Trichloro-N-(5,5-dimethyl-7-oxo-4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)benzenesulfonamide
  参考文献：
  名称：

  Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

  摘要：

  本发明涉及使用具有以下化学式（I）的化合物，其中T是（I）噻吩基，它可以用卤素取代，或者（II）苯基，它可以用卤素和/或C1-6烷基取代；E是键，-CH2-或-CO-;L是键，-CH2-，-CHR4-或-NR3-;R3是H，C1-6烷基，C1-6酰基或-COR4;R4是吗啡基或C1-6酰胺基;R6和R7独立地是氢或C1-6烷基;R8和R9独立地是氢或C1-6烷基，以及其药学上可接受的盐，水合物和溶剂化物，在制造用于治疗或预防糖尿病，X综合症，肥胖症，青光眼，高脂血症，高血糖，高胰岛素血症，骨质疏松症，结核病，痴呆症，抑郁症，病毒病和炎症性疾病的药物。

  公开号：

  US20030199501A1

文献信息

• Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
  申请人：Biovitrum AB

  公开号：US07030135B2

  公开（公告）日：2006-04-18

  The present invention relates to using a compound having the formula (I) wherein T is I) thienyl, which optionally is substituted with halogen, or II) phenyl optionally substituted with halogen and/or C1-6-alkyl; E is a bond, —CH2— or —CO—; L is a bond, —CH2—, —CHR4— or —NR3—; R3 is H, C1-6-alkyl, C1-6-acyl or —COR4; R4 is morpholino or C1-6-amido; R6 and R7 are independently hydrogen or C1-6-alkyl; and R8 and R9 are independently hydrogen or C1-6-alkyl, as well as pharmaceutically acceptable salts, hydrates and solvates thereof, in the manufacture of a medicament for the treatment or prevention of diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, osteoporosis, tuberculosis, dementia, depression, virus diseases and inflammatory disorders.

  本发明涉及使用具有以下式子（I）的化合物，其中T是I）噻吩基，可以用卤素取代，或II）苯基，可以用卤素和/或C1-6烷基取代；E是键，-CH2-或-CO-；L是键，-CH2-，-CHR4-或-NR3-；R3是H，C1-6烷基，C1-6酰基或-COR4；R4是吗啡环或C1-6酰胺基；R6和R7分别是氢或C1-6烷基；R8和R9分别是氢或C1-6烷基，以及其药学上可接受的盐、水合物和溶剂合物，用于制备治疗或预防糖尿病、综合征X、肥胖症、青光眼、高脂血症、高血糖、高胰岛素血症、骨质疏松症、结核病、痴呆症、抑郁症、病毒性疾病和炎症性疾病的药物。
• INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1
  申请人：BIOVITRUM AB

  公开号：EP1283834A1

  公开（公告）日：2003-02-19
• US7030135B2
  申请人：——

  公开号：US7030135B2

  公开（公告）日：2006-04-18
• [EN] INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1<br/>[FR] INHIBITEURS DE 11-BETA-HYDROXY-STEROIDE-DESHYDROGENASE DE TYPE 1
  申请人：BIOVITRUM AB

  公开号：WO2001090094A1

  公开（公告）日：2001-11-29

  The present invention relates to using a compound having the formula (I) wherein T is I) thienyl, which optionally is substituted with halogen, or II) phenyl optionally substituted with halogen and/or C1-6-alkyl; E is a bond, -CH2- or -CO-; L is a bond, -CH2-, -CHR4- or -NR3-; R3 is H, C¿1-6?-alkyl, C1-6-acyl or -COR?4; R4¿ is morpholino or C¿1-6?-amido; R?6 and R7¿ are independently hydrogen or C¿1-6?-alkyl; and R?8 and R9¿ are independently hydrogen or C¿1-6?-alkyl, as well as pharmaceutically acceptable salts, hydrates and solvates thereof, in the manufacture of a medicament for the treatment or prevention of diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, osteoporosis, tuberculosis, dementia, depression, virus diseases and inflammatory disorders.
• [EN] NEW USE III<br/>[FR] NOUVELLE UTILISATION III
  申请人：BIOVITRUM AB

  公开号：WO2004112785A1

  公开（公告）日：2004-12-29

  The invention relates to a method for promoting wound healing, said method comprising administering to a mammal, including man, in need of such promotion an effective amount of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 (11b-HSD1), said 11b-HSD1 inhibitor having the formula (I) wherein T, E, L, R6, R7, R8 and R9 are as defined in the specification. These compounds may also be used in the manufacture of a medicament for promoting wound healing.